Services

Histology

Pharmacology

Medical Device Testing

In Vitro Screening

Animal Model Development

Custom Assay Development

Vivarium Rental

Toxicology

Species

Non-human Primates

Dogs

Mini-pigs / Pigs

Rabbits

Mice

Rats

Sheep

Guinea Pigs

Hamsters

Other Species

Therapeutic Areas

Oncology

Immunology & Inflammation

Neurology / CNS

Cardiovascular

Dermatology & Wound Healing

Metabolism

Gastroenterology

Hepatology

Pulmonology

Infectious Diseases & Sepsis

Musculoskeletal

Nephrology & Urology

Capabilities

GLP / IND-Enabling Studies

Small and Large Animal Housing

Bioanalytical Platforms

About

News

Contact

Career

Request a Quote

Logo
☰
  • Services ⌄
    • Histology
    • Pharmacology
    • Medical Device Testing
    • In Vitro Screening
    • Animal Model Development
    • Custom Assay Development
    • Vivarium Rental
    • Toxicology
  • Species ⌄
    • Non-human Primates
    • Dogs
    • Mini-pigs / Pigs
    • Rabbits
    • Mice
    • Rats
    • Sheep
    • Guinea Pigs
    • Hamsters
    • Other Species
  • Therapeutic Areas ⌄
    • Oncology
    • Immunology & Inflammation
    • Neurology / CNS
    • Cardiovascular
    • Dermatology & Wound Healing
    • Metabolism
    • Gastroenterology
    • Hepatology
    • Pulmonology
    • Infectious Diseases & Sepsis
    • Musculoskeletal
    • Nephrology & Urology
  • Capabilities ⌄
    • GLP / IND-Enabling Studies
    • Small and Large Animal Housing
    • Bioanalytical Platforms
  • About ⌄
    • News
  • Contact ⌄
    • Career
    • Request a Quote

Quick Notes: Drug Approvals — Feb. 20, 2024

  • Post author:PacConAdmin
  • Post published:February 20, 2024
  • Post category:Uncategorized
  • Post comments:0 Comments

This edition of Quick Notes looks at consequential new drug approvals, including a first drug for frostbite, a first of its kind gene therapy authorization for sickle cell disease and…

Continue ReadingQuick Notes: Drug Approvals — Feb. 20, 2024

New Ruling Revives Lawsuit Against Sanofi for “Low Dosing” Fabry Disease Drug

  • Post author:PacConAdmin
  • Post published:February 20, 2024
  • Post category:Uncategorized
  • Post comments:0 Comments

Judges from the U.S. District Court of Massachusetts have revived a nearly 12-year-old lawsuit that charged Sanofi with damaging the health of patients with a rare liver disease by selling…

Continue ReadingNew Ruling Revives Lawsuit Against Sanofi for “Low Dosing” Fabry Disease Drug

Combatting Substance Abuse Highlights CDER’s 2023 Accomplishments

  • Post author:PacConAdmin
  • Post published:February 16, 2024
  • Post category:Uncategorized
  • Post comments:0 Comments

The historic 2023 approval of OTC naloxone was a highlight of the FDA’s efforts to combat the opioid overdose crisis, according to CDER’s year-end report on drug safety actions. Source:…

Continue ReadingCombatting Substance Abuse Highlights CDER’s 2023 Accomplishments

Two Pharma Behemoths Reach Contrasting Settlement Agreements

  • Post author:PacConAdmin
  • Post published:February 16, 2024
  • Post category:Uncategorized
  • Post comments:0 Comments

Despite its denial of any wrongdoing, Pfizer has agreed to a settlement payment of $93 million to finally erase 12 years of antitrust litigation with drug distributors involving Lipitor, the…

Continue ReadingTwo Pharma Behemoths Reach Contrasting Settlement Agreements

Senators Urge FDA to Crack Down on Misleading Social Media Prescription Drug Ads

  • Post author:PacConAdmin
  • Post published:February 16, 2024
  • Post category:Uncategorized
  • Post comments:0 Comments

Senate Majority Whip Dick Durbin (D-Ill.) and Senator Mike Braun (R-Ind.) have urged the FDA to take “swift” action to update its enforcement tools to address the alarming proliferation of…

Continue ReadingSenators Urge FDA to Crack Down on Misleading Social Media Prescription Drug Ads

Regulatory Update — Week of Feb. 12, 2024

  • Post author:PacConAdmin
  • Post published:February 16, 2024
  • Post category:Uncategorized
  • Post comments:0 Comments

Over the past week, the FDA issued a final rule on BLAs and master files. Final Guidance was issued on charging for investigational drugs under an IND. Draft guidance was issued…

Continue ReadingRegulatory Update — Week of Feb. 12, 2024

Dayton Chamber’s Suit Against the IRA Lacks Standing, Should Be Dismissed, HHS Says

  • Post author:PacConAdmin
  • Post published:February 16, 2024
  • Post category:Uncategorized
  • Post comments:0 Comments

The Dayton Chamber of Commerce doesn’t represent any of the pharmaceutical giants affected by the drug negotiation provision of the Inflation Reduction Act (IRA), HHS says in its motion to…

Continue ReadingDayton Chamber’s Suit Against the IRA Lacks Standing, Should Be Dismissed, HHS Says

FDA Finalizes Guidance on Charging for Investigational Drugs, Takes Other Actions

  • Post author:PacConAdmin
  • Post published:February 15, 2024
  • Post category:Uncategorized
  • Post comments:0 Comments

The FDA has issued final guidance on charging for investigational new drugs in clinical trials, offering a minor update to its recommendations. In addition, the agency has published new draft…

Continue ReadingFDA Finalizes Guidance on Charging for Investigational Drugs, Takes Other Actions

Quick Notes: Device News — Feb. 15, 2024

  • Post author:PacConAdmin
  • Post published:February 15, 2024
  • Post category:Uncategorized
  • Post comments:0 Comments

This week, your watch can start alerting you to sleep apnea, a fingertip clip can monitor your daytime blood oxygen, and a robotic exoskeleton can help restore mobility to spinal…

Continue ReadingQuick Notes: Device News — Feb. 15, 2024

Califf Calls for Greater Accuracy, Balance in Health Care Reporting

  • Post author:PacConAdmin
  • Post published:February 15, 2024
  • Post category:Uncategorized
  • Post comments:0 Comments

The presentation and accuracy of medical information through traditional and social media — and even the headlines that accompany it — directly impact the nation’s health, FDA Commissioner Robert Califf…

Continue ReadingCaliff Calls for Greater Accuracy, Balance in Health Care Reporting
  • Go to the previous page
  • 1
  • …
  • 74
  • 75
  • 76
  • 77
  • 78
  • 79
  • 80
  • …
  • 144
  • Go to the next page

Stay Connected

Keep up with the latest news & insights.

Contact Us

Phone:
+1 858-605-5882
Fax:
+1 858-605-5916
Email:
info@biolegacyresearch.com
Mail:

6042 Cornerstone Court W

Suite E

San Diego, CA 92121

Social:
© 2025 BioLegacy Research. All rights reserved.